noscript

News and Announcements

New partnership with NZ’s Orbis Diagnostics to accelerate health solutions for remote and rural communities

  • Published June 02, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

The development and delivery of new diagnostic solutions to remote communities in Australia, New Zealand  and internationally is the goal of a new strategic partnership between Australian medical research organisation,  Burnet Institute, and New Zealand biotech company, Orbis Diagnostics. 

The partnership will bring together Burnet’s research excellence and Orbis’ expertise in the production of  lab-quality, point-of-care diagnostics to accelerate the development of a suite of finger-prick blood tests for  infectious disease and liver health. 

Jennifer Barnes, Director of Burnet Diagnostics Initiative said developing simple, accurate diagnostic tests that  can be easily operated in remote and rural areas is essential to improving the health of communities globally.  

“A key challenge to delivering health care in rural communities is access. Removing the waiting time for  diagnostic test results will be a major step towards helping address this challenge. Our focus has been on the  development of lateral flow tests, but the partnership with Orbis Diagnostics will allow us to develop our  biomarkers into multiple test formats and reach more communities in need,” Ms Barnes said.  

Register Interest

“We are pleased to continue our commitment to deliver lab-quality testing to remote and resource-limited  communities to improve health security and aid in disease elimination both at home in Australia and globally.”  

Orbis Chief Executive, Damian Camp said the opportunity to partner with Burnet Institute is a significant step  towards applying Orbis’ miniaturised, automated pathology lab solution to address the challenges with  delivering health care to rural populations.  

“We understand access is a major barrier for many people who live in remote locations. Because our diagnostic  technology platform is specifically designed to provide quick and accurate information about a persons’ health,  at point of need, we can help overcome this barrier so that the right healthcare is provided where and when it  is needed,” he said. 

“The partnership will involve developing a suite of diagnostic screening products. The type of tests offered will  be based on high need but could span analysing a person’s liver function right through to testing for sexually  transmitted diseases. 

“Through our COVID-19 immunity test, we’ve successfully demonstrated our technology has huge potential to  run a number of diagnostic tests at the point of care. We’re aiming to run a real-world pilot of our diagnostic  testing solutions in a remote location in the next 12 months.” 

With comparable accuracy to the complex tests available in medical labs, each Orbis device is capable of testing  up to eight people at a time and reporting results within 15 minutes from a finger-prick sample, making it a  robust, cost-effective, scalable, and practical solution to support delivery of rural health services. 

Ms Barnes said Burnet Institute brings over 30 years of expertise in translating diagnostic research into practical  products that help individuals better manage their health.  

“We’re excited to be collaborating with Orbis Diagnostics to translate our research into practical diagnostic solutions for unmet health needs,” she said. 

About Orbis Diagnostics: 

Orbis Diagnostics is a next-generation point-of-care diagnostics company that is transforming community-based  healthcare. Powered by microfluidic and photonic innovations, Orbis’ automated desktop system successfully  miniaturises the medical lab to delivering real-time, actionable test results from a finger-prick of blood. Leaders  in the primary healthcare sector are working with Orbis to deploy its technology and support time-critical  healthcare decision-making at the point of care. The first test available is a quantitative COVID-19 antibody test  that measures a person’s individual immune response from vaccination or prior infection. Orbis is developing a  comprehensive portfolio of diagnostic solutions that will improve health outcomes by making routine blood  testing more convenient and accessible.  

About Burnet Institute: 

Burnet Institute is an independent, not-for-profit, medical research institute passionate about social justice,  equality and evidence-based research. Our purpose is to create and translate knowledge into better health, so  no-one is left behind. The Burnet Diagnostics Initiative was formed to commercialise the Institute’s point-of-care  diagnostics research, including a broad range of projects to address syphilis, liver function, HIV and COVID-19.

Register Interest

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now